

Sales of Therapeutic Antibodies 2006 - 2012

Antibody group	Selected branded products	Sales in US\$ bln						
		2006	2007	2008	2009	2010	2011	2012
Cancer Antibodies	Rituxan/MabThera, Herceptin, Avastin, Erbitux, Vectibix, Arzerra, Zevalin, XGEVa	10.62	15.74	15.59	18.18	21.98	21.38	23.74
Anti-TNF Antibodies	Enbrel, Remicade, Humira, Cimzia, Simponi	10.28	12.98	16.36	18.10	20.95	23.74	26.68
Other Anti-Inflammatory Antibodies	Tysabri, Xolair, Orencia, Soliris, Amevive, RoActemra, Arcalyst, Stelara, Ilaris ...	0.77	1.73	2.02	3.12	4.08	5.83	7.30
Ophthalmic Antibodies	Lucentis, Eylea	0.38	1.36	1.76	2.34	3.11	3.78	4.83
Anti-Viral Antibody	Synagis	1.1	1.13	1.23	1.08	1.04	0.98	1.04
Other Antibodies	ReoPro, Prolia, Nplate	0.28	0.27	0.26	0.23	0.47	0.67	0.98
Total		23.43	33.21	37.22	43.05	51.63	56.38	64.57
Annual Growth Rate vs previous year (%)			41.7%	12.1%	15.7%	20.0%	9.2%	14.5%

Average/continuous annual growth rate (**CAGR**) from 2006 to 2012: **18.9%**

In 2012, for the first time sales of antibodies (US\$ 64.6 bln) were higher than those of proteins (US\$ 60.4 bln)

All data were taken from the annual sales compilations published by La Merie Publishing on www.pipelinereview.com